High throughput development of TCR-mimic sdAbs
TCRm antibodies
Traditional antibody therapy is limited to targeting cell surface antigens, leaving intracellular proteins, which are the majority of tumor-specific antigens, untouched. To address this issue, TCR-mimic antibodies have been developed. These antibodies recognize the peptide/MHC complexes on the surface of tumor cells, triggering a broad range of pharmacological pathways, including ADCC, CDC, ADCP, and apoptosis induction. TCR-minic antibodies can also be modified into a CAR structure to mediate cell immunity.
NBbiolab TCR-mimic sdAbs
Features of NBbiolab TCR-mimic sdAbs platform
High-quality library construction based on yeast surface display technology.
Compatible with flow cytometry to precisely control screening parameters.
Enhanced antibody identifification through NGS analysis.
Extensive project experience ensures a high success rate.
Tel：+86 4008677715
E-mail：service@nb-biolab.com
Address：SME Incubation Park, 319 Qingpi Avenue, Chengdu, China.
Working time：9:00-18:00